170
Participants
Start Date
December 18, 2023
Primary Completion Date
December 12, 2025
Study Completion Date
December 12, 2027
HS-20093
Participants in all subjucts will receive HS-20093 at 10mg/kg
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Anhui Cancer Hospital, Hefei
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Beijing Tongren Hospital, CMU, Beijing
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yai-Sen Memorial Hospital Sun Yai-Sen University, Guangzhou
RECRUITING
Sun Yat-Sen University Cancer Center, Guangzhou
RECRUITING
The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
The Second XIANGYA Hospital Of Central South University, Changsha
NOT_YET_RECRUITING
The Second Hospital of Dalian Medical University, Dalian
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
RECRUITING
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
RECRUITING
The first Affiliated Hospital of Xi'an Jiaotong University, Xi’an
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Cancer hospital of Xinjiang medical University, Xinjiang
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
Hansoh BioMedical R&D Company
INDUSTRY